Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
President Biden signs his first executive orders reversing several Trump administration actions, including rejoining the Paris Agreement and the World Health Organization, repealing the 2017 travel bans, ending funding for the Mexico–United States border wall, and revoking the permit for the Keystone XL pipeline. January 21 – The Food and Drug Administration (FDA) approves Cabenuva as a complete regimen for the treatment of HIV/AIDS. January 22 – Recreational cannabis sales begin in Arizona. January 24 COVID-19 pandemic: Nationwide confirmed COVID-19 cases surpass 25 million. The Tampa Bay Buccaneers advance to Super Bowl LV after a 31–26 victory against the Green Bay Packers, the first time an NFL team will play the Super Bowl on their home field. January 25 President Biden repeals the Trump administration's ban on transgender personnel in the military. COVID-19 pandemic: Minnesota reports the first national case of the Lineage P.1 variant of SARS-CoV-2. Dominion Voting Systems sues former New York City mayor Rudy Giuliani, accusing him of defamation during the 2020 presidential election. January 26 COVID-19 pandemic: The Biden administration announces it will purchase 200 million COVID-19 vaccine doses from Pfizer/BioNTech and Moderna, in addition to the prior order of 400 million. January 27 The U.S. Army announces new personal grooming and appearance standards, relaxing rules regarding makeup and jewelry and allowing for more diverse hairstyles.
The chemical nature of the stationary phase. The stationary phase can be coated with some ligands at different bonding densities (how many ligands are bonded per surface area). The composition of the mobile phase. The mobile phase may be made of one solvent, or a mixture of several solvents. The solvents can be mixed at different ratios. Different mobile phases have different properties, such as polarity. When a mobile phase consists of mostly one solvent, with some other solvents added in small amounts, those other solvents are called "mobile phase modifiers". The pH of the mobile phase, which affect the ionization state of the solutes and their polarity. This can be changed with additives such as buffers. Usually, the stationary phase is made of a layer of hydrophobic substrate bonded to the surface of porous silica gel particles. The particles come in various shapes (spheric, irregular), at different diameters (sub-2, 3, 5, 7, 10 μm), with varying pore diameters (60, 100, 150, 300 Å). The particle diameters are often given as mesh numbers. For example, 2500-mesh corresponds to a particle diameter of 5 μm. The hydrophobic substrates are generally alkyl chains, such as C3, C4, C8, C18, or more. The longer the chain, the longer the sample components will be retained. It would make the resolution power higher, but also make the chromatography take longer to run. Most current methods of separation of biomedical materials use C18 columns, sometimes called by trade names, such as ODS (octadecylsilane) or RP-18 (reverse phase 18).
The 15N HSQC experiment is one of the most frequently recorded experiments in protein NMR. The HSQC experiment can be performed using the natural abundance of the 15N isotope, but normally for protein NMR, isotopically labeled proteins are used. Such labelled proteins are usually produced by expressing the protein in cells grown in 15N-labelled media. Each residue of the protein, with the exception of proline, has an amide proton attached to a nitrogen in the peptide bond. The HSQC provides the correlation between the nitrogen and amide proton, and each amide yields a peak in the HSQC spectra. Each residue (except proline) therefore can produce an observable peak in the spectra, although in practice not all the peaks are always seen due to a number of factors. Normally the N-terminal residue (which has an NH3+ group attached) is not readily observable due to exchange with solvent. In addition to the backbone amide resonances, sidechains with nitrogen-bound protons will also produce peaks. In a typical HSQC spectrum, the NH2 peaks from the sidechains of asparagine and glutamine appear as doublets on the top right corner, and a smaller peak may appear on top of each peak due to deuterium exchange from the D2O normally added to an NMR sample, giving these sidechain peaks a distinctive appearance. The sidechain amine peaks from tryptophan are usually shifted downfield and appear near the bottom left corner. The backbone amide peaks of glycine normally appear near the top of the spectrum.
The Br–Br distance is 227 pm (close to the gaseous Br–Br distance of 228 pm) and the Br···Br distance between molecules is 331 pm within a layer and 399 pm between layers (compare the van der Waals radius of bromine, 195 pm). This structure means that bromine is a very poor conductor of electricity, with a conductivity of around 5 × 10−13 Ω−1 cm−1 just below the melting point, although this is higher than the essentially undetectable conductivity of chlorine. At a pressure of 55 GPa (roughly 540,000 times atmospheric pressure) bromine undergoes an insulator-to-metal transition. At 75 GPa it changes to a face-centered orthorhombic structure. At 100 GPa it changes to a body centered orthorhombic monatomic form.
Enzymes are bio-catalysts which play an essential role in the enhancement of chemical reactions in cells without being persistently modified, wasted, nor resulting in the loss of equilibrium of chemical reactions. Although the characteristics of enzymes are extremely unique, their utility in the industry is limited due to the lack of re-usability, stability, and high-cost of production.
Sources: en.wikipedia.org
=== Therapeutic foods === Due in part to limited research on supplementary feeding, there is little evidence that this strategy is beneficial. A 2015 systematic review of 32 studies found that there are limited benefits when children under 5 receive supplementary feeding, especially among younger, poorer, and more undernourished children. However, specially formulated foods do appear to be useful in treating moderate acute malnutrition in the developing world. These foods may have additional benefits in humanitarian emergencies, since they can be stored for years, can be eaten directly from the packet, and do not have to be mixed with clean water or refrigerated. In young children with severe acute malnutrition, it is unclear if ready-to-use therapeutic food differs from a normal diet. Severely malnourished individuals can experience refeeding syndrome if fed too quickly. Refeeding syndrome can result regardless of whether food is taken orally, enterally or parenterally. It can present several days after eating with potentially fatal heart failure, dysrhythmias, and confusion. Some manufacturers have fortified everyday foods with micronutrients before selling them to consumers. For example, flour has been fortified with iron, zinc, folic acid, and other B vitamins like thiamine, riboflavin, niacin and vitamin B12. Baladi bread (Egyptian flatbread) is made with fortified wheat flour. Other fortified products include fish sauce in Vietnam and iodized salt.
Norman architecture typically stands out as a new stage in the architectural history of the regions they subdued. They spread a unique Romanesque idiom to England, Italy and Ireland, and the encastellation of these regions with keeps in their north French style fundamentally altered the military landscape. Their style was characterised by rounded arches, particularly over windows and doorways, and massive proportions. In England, the period of Norman architecture immediately succeeds that of the Anglo-Saxon and precedes the Early Gothic. In southern Italy, the Normans incorporated elements of Islamic, Lombard, and Byzantine building techniques into their own, initiating a unique romanesque style known as Norman-Arab architecture within the Kingdom of Sicily and precedes the Early Gothic.
=== Triggers === With low phosphate levels, P. aeruginosa has been found to activate from benign symbiont to express lethal toxins inside the intestinal tract and severely damage or kill the host, which can be mitigated by providing excess phosphate instead of antibiotics.
This selection influences the flavour of the coffee, as does the digestive process. The beans begin to germinate by malting, which reduces their bitterness. When performed in nature, or in the wild, these two mechanisms achieve the same goal as selective picking and the wet or washed process of coffee milling: 1) harvesting optimally ripe cherries and 2) mechanically and chemically removing the pulp and skin from the cherry, leaving mainly the seed. Traditionally, excreted coffee beans were collected directly in plantations and forests. As the international demand for kopi luwak increased, some producers turned to caged production methods to increase yields. It is produced in Indonesia, East Timor, the Philippines, Thailand, Vietnam and Ethiopia.
Sources: en.wikipedia.org
=== Locations === Stumptown operates five cafes in Portland. They are located on SE 45th & Division St., SE 34th & Belmont, downtown at SW 3rd & Ash St., inside the Ace Hotel at 1022 SW Stark Street, and at the Portland International Airport. The company also owns a roasting facility and a retail annex inside their headquarters at 100 SE Salmon St. The original location on SE Division was previously a hair salon called "The Hair Bender," whose name Stumptown adopted for one of their signature espresso blends. In November 2007, Stumptown opened two cafes in Seattle. In September 2009, the company also launched a cafe in New York's Ace Hotel. A temporary "pop-up" location appeared in Amsterdam's De Pijp neighborhood in May 2010. Opened by Sorenson, he claimed it was never intended to be permanent and closed its doors that same year. In 2013, Stumptown opened a second New York City café and a café/roaster in Los Angeles. Additional cafes have also opened in Chicago and New Orleans. Stumptown opened their third New York cafe in a historic Brooklyn firehouse in the summer of 2018. A location at the Portland International Airport opened in 2024.
=== Drug target === POMC is a pharmacological target for obesity treatment. The combination drug naltrexone/bupropion acts on hypothalamic POMC neurons to reduce appetite and food intake. In rare cases of POMC deficiency, treatment with setmelanotide, a selective melanocortin-4 receptor agonist, has been effective. Two individuals with confirmed POMC deficiency showed clinical improvement following this therapy.
=== Pharmacokinetics === Oclacitinib is absorbed well when taken orally; it takes less than an hour to reach peak plasma concentration and has a bioavailability of 89%. In most dogs, pruritus begins to subside within four hours and is completely gone within 24. Oclacitinib is cleared mostly by being metabolized in the liver, though there is some kidney and bile duct clearance as well.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.